Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Frailty and anticoagulants in older subjects with atrial fibrillation: the EUROSAF study

A. Pilotto, N. Veronese, MC. Polidori, T. Strandberg, E. Topinkova, AJ. Cruz-Jentoft, C. Custodero, M. Barbagallo, S. Maggi, EUROSAF Study Investigators

. 2023 ; 52 (11) : . [pub] 20231102

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc24020056

Grant support
European Geriatric Medicine Society

AIMS: Literature regarding anticoagulants in older people affected by atrial fibrillation (AF) is limited to retrospective studies, poorly considering the importance of multidimensional frailty. The main objective of this study is to evaluate in hospitalised older persons with AF the benefit/risk ratio of the anticoagulant treatments, considering the severity of frailty, determined by the multidimensional prognostic index (MPI). METHODS: In this European, multicentre, prospective study, older hospitalised patients (≥65 years) with non-valvular AF were followed-up for 12 months. Anticoagulants' use at discharge ascertained using medical records. MPI was calculated using tools derived from comprehensive geriatric assessment, classifying participants in robust, pre-frail or frail. Mortality (primary outcome); vascular events, including ischemic heart disease or ischemic stroke, hemorrhagic stroke or gastrointestinal bleedings (secondary outcomes). RESULTS: 2,022 participants (mean age 82.9 years; females 56.6%) were included. Compared with people not taking anticoagulants (n = 823), people using vitamin K antagonists (n = 450) showed a decreased risk of mortality (hazard ratio, HR = 0.74; 95% CI: 0.59-0.93), more pronounced in patients using direct oral anticoagulants (DOACs) (n = 749) (HR = 0.46; 95% CI: 0.37-0.57). Only people taking DOACs reported a significantly lower risk of vascular events (HR = 0.55; 95% CI: 0.31-0.97). The efficacy of DOACs was present independently from frailty status. The risk of gastrointestinal bleedings and hemorrhagic stroke did not differ based on the anticoagulant treatments and by MPI values. CONCLUSIONS: Anticoagulant treatment, particularly with DOACs, was associated with reduced mortality in older people, without increasing the risk of hemorrhagic events, overall suggesting the importance of treating with anticoagulants older people with AF.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24020056
003      
CZ-PrNML
005      
20241024110909.0
007      
ta
008      
241015s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ageing/afad216 $2 doi
035    __
$a (PubMed)39248098
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pilotto, Alberto $u Geriatrics Unit, Department of Geriatric Care, OrthoGeriatrics and Rehabilitation, E.O. Galliera Hospital, Genova, Italy $u Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy
245    10
$a Frailty and anticoagulants in older subjects with atrial fibrillation: the EUROSAF study / $c A. Pilotto, N. Veronese, MC. Polidori, T. Strandberg, E. Topinkova, AJ. Cruz-Jentoft, C. Custodero, M. Barbagallo, S. Maggi, EUROSAF Study Investigators
520    9_
$a AIMS: Literature regarding anticoagulants in older people affected by atrial fibrillation (AF) is limited to retrospective studies, poorly considering the importance of multidimensional frailty. The main objective of this study is to evaluate in hospitalised older persons with AF the benefit/risk ratio of the anticoagulant treatments, considering the severity of frailty, determined by the multidimensional prognostic index (MPI). METHODS: In this European, multicentre, prospective study, older hospitalised patients (≥65 years) with non-valvular AF were followed-up for 12 months. Anticoagulants' use at discharge ascertained using medical records. MPI was calculated using tools derived from comprehensive geriatric assessment, classifying participants in robust, pre-frail or frail. Mortality (primary outcome); vascular events, including ischemic heart disease or ischemic stroke, hemorrhagic stroke or gastrointestinal bleedings (secondary outcomes). RESULTS: 2,022 participants (mean age 82.9 years; females 56.6%) were included. Compared with people not taking anticoagulants (n = 823), people using vitamin K antagonists (n = 450) showed a decreased risk of mortality (hazard ratio, HR = 0.74; 95% CI: 0.59-0.93), more pronounced in patients using direct oral anticoagulants (DOACs) (n = 749) (HR = 0.46; 95% CI: 0.37-0.57). Only people taking DOACs reported a significantly lower risk of vascular events (HR = 0.55; 95% CI: 0.31-0.97). The efficacy of DOACs was present independently from frailty status. The risk of gastrointestinal bleedings and hemorrhagic stroke did not differ based on the anticoagulant treatments and by MPI values. CONCLUSIONS: Anticoagulant treatment, particularly with DOACs, was associated with reduced mortality in older people, without increasing the risk of hemorrhagic events, overall suggesting the importance of treating with anticoagulants older people with AF.
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x farmakoterapie $x mortalita $x komplikace $x diagnóza $7 D001281
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a senioři $7 D000368
650    12
$a antikoagulancia $x terapeutické užití $x škodlivé účinky $7 D000925
650    _2
$a prospektivní studie $7 D011446
650    12
$a křehký senior $x statistika a číselné údaje $7 D016330
650    12
$a geriatrické hodnocení $7 D015577
650    _2
$a hodnocení rizik $7 D018570
650    12
$a křehkost $x mortalita $x diagnóza $7 D000073496
650    _2
$a rizikové faktory $7 D012307
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Veronese, Nicola $u Geriatrics Unit, Department of Internal Medicine, University of Palermo, Palermo, Italy
700    1_
$a Polidori, Maria Cristina $u Ageing Clinical Research, Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
700    1_
$a Strandberg, Timo $u University of Helsinki and Helsinki University Hospital, Helsinki Finland $u Center for Life Course Health Research, University of Oulu, Oulu, Finland
700    1_
$a Topinkova, Eva $u First Faculty of Medicine, Charles University in Prague, Czech Republic
700    1_
$a Cruz-Jentoft, Alfonso J $u Servicio de Geriatría, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain
700    1_
$a Custodero, Carlo $u Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy $1 https://orcid.org/0000000315496451
700    1_
$a Barbagallo, Mario $u Geriatrics Unit, Department of Internal Medicine, University of Palermo, Palermo, Italy
700    1_
$a Maggi, Stefania $u National Research Council, Neuroscience Section, Padova, Italy
710    2_
$a EUROSAF Study Investigators
773    0_
$w MED00000173 $t Age and ageing $x 1468-2834 $g Roč. 52, č. 11 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39248098 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110903 $b ABA008
999    __
$a ok $b bmc $g 2202350 $s 1232029
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 52 $c 11 $e 20231102 $i 1468-2834 $m Age and ageing $n Age Ageing $x MED00000173
GRA    __
$p European Geriatric Medicine Society
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options